December 28, 2006

Denufosol, a potential new therapeutic for CF, has just been listed as one of the top five most promising drugs entering phase 3 clinical trials according to industry analyst, Thomson Pharma. Created by Inspire Pharmaceuticals, denufosol is designed to improve chloride transport in CF airways and enhance mucosal hydration and clearance. CF patients who took denufosol in a Phase 2 clinical trial had significantly better lung function than patients taking placebo at the end of that trial.

Denufosol has received Fast Track and Orphan Drug status in the United States. Recruitment for a Phase 3 clinical trial is ongoing. For more information, go to www.inspirepharm.com or call (919) 287-1286.